Cagent Vascular Reports First Human Use of Serranator® SONIC IVL System and Closes Oversubscribed $41M Series D Financing
Cagent Vascular, Inc. has announced the successful completion of the first human-use cases with its Serranator SONIC IVL System. The company also closed an oversubscribed Series D round of financing, raising $41 million.
WAYNE, Pa.–(BUSINESS WIRE)– #CLI–Cagent Vascular, Inc. announces completion of first human-use cases with the Serranator SONIC IVL System and closing of $41 million Series D round.